BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

608 related articles for article (PubMed ID: 18786076)

  • 1. Intravenous iron in chronic kidney disease: haemoglobin change shortly after treatment of patients neither on dialysis nor on erythropoietin.
    Tagboto S; Cropper L; Mostafa S; Turner J; Bailey G; Pugh-Clarke K
    J Ren Care; 2008 Sep; 34(3):112-5. PubMed ID: 18786076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients.
    Mircescu G; Gârneata L; Capusa C; Ursea N
    Nephrol Dial Transplant; 2006 Jan; 21(1):120-4. PubMed ID: 16144853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder.
    Geisser P; Rumyantsev V
    Arzneimittelforschung; 2010; 60(6a):373-85. PubMed ID: 20648929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should we limit the ferritin upper threshold to 500 ng/ml in CKD patients?
    Dukkipati R; Kalantar-Zadeh K
    Nephrol News Issues; 2007 Jan; 21(1):34-8. PubMed ID: 17269263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving efficiency and value in health care. Intravenous iron management for anaemia associated with chronic kidney disease: linking treatment to an outpatient clinic, optimizing service provision and patient choice.
    Bhandari S; Naudeer S
    J Eval Clin Pract; 2008 Dec; 14(6):996-1001. PubMed ID: 18785894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pentoxifylline improves haemoglobin and interleukin-6 levels in chronic kidney disease.
    Ferrari P; Mallon D; Trinder D; Olynyk JK
    Nephrology (Carlton); 2010 Apr; 15(3):344-9. PubMed ID: 20470305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of C-reactive protein, reticulocyte haemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients.
    El-Khatib M; Duncan HJ; Kant KS
    Nephrology (Carlton); 2006 Oct; 11(5):400-4. PubMed ID: 17014552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical review of the newer intravenous iron therapy options.
    Edwards JH
    Nephrol Nurs J; 2003 Feb; 30(1):70-3. PubMed ID: 12674953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proposed therapeutic algorithm for the treatment of anemia of chronic renal failure in pre-dialysis patients with low dose once weekly subcutaneous r-HuEPO. Multicenter Study Group, Israel.
    Yagil Y
    Isr J Med Sci; 1997 Jan; 33(1):36-44. PubMed ID: 9203516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial.
    Charytan C; Levin N; Al-Saloum M; Hafeez T; Gagnon S; Van Wyck DB
    Am J Kidney Dis; 2001 Feb; 37(2):300-7. PubMed ID: 11157370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized evaluation of efficacy and safety of ferric carboxymaltose in patients with iron deficiency anaemia and impaired renal function (REPAIR-IDA): rationale and study design.
    Szczech LA; Bregman DB; Harrington RA; Morris D; Butcher A; Koch TA; Goodnough LT; Wolf M; Onken JE
    Nephrol Dial Transplant; 2010 Jul; 25(7):2368-75. PubMed ID: 20466657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
    Li H; Wang SX
    Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Iron replacement in hemodialysis patients with a normal serum ferritin level].
    Riedel MK; Morgenstern T
    Dtsch Med Wochenschr; 2004 Sep; 129(36):1849-53. PubMed ID: 15368155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: a randomized controlled trial.
    McMahon LP; Kent AB; Kerr PG; Healy H; Irish AB; Cooper B; Kark A; Roger SD
    Nephrol Dial Transplant; 2010 Mar; 25(3):920-6. PubMed ID: 19906658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease.
    Wikström B; Bhandari S; Barany P; Kalra PA; Ladefoged S; Wilske J; Thomsen LL
    J Nephrol; 2011; 24(5):589-96. PubMed ID: 21240875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients.
    Schiesser D; Binet I; Tsinalis D; Dickenmann M; Keusch G; Schmidli M; Ambühl PM; Lüthi L; Wüthrich RP
    Nephrol Dial Transplant; 2006 Oct; 21(10):2841-5. PubMed ID: 16891647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficiency of fractionated parenteral iron treatment in CAPD patients.
    Akcicek F; Ozkahya M; Cirit M; Ok E; Unsal A; Toz H; Celik A; Atabay G; Basci A
    Adv Perit Dial; 1997; 13():109-12. PubMed ID: 9360661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous iron dextran treatment in predialysis patients with chronic renal failure.
    Dahdah K; Patrie JT; Bolton WK
    Am J Kidney Dis; 2000 Oct; 36(4):775-82. PubMed ID: 11007680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
    Chen YC; Hung SC; Tarng DC
    Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of response to iron sucrose in inflammatory bowel disease-associated anemia.
    Gasche C; Waldhoer T; Feichtenschlager T; Male C; Mayer A; Mittermaier C; Petritsch W;
    Am J Gastroenterol; 2001 Aug; 96(8):2382-7. PubMed ID: 11513178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.